Evidence Explorer · MS-N300 · Nutraceuticals · Supportive care · Appraised 11 November 2026
Small randomized trials suggest oral N-acetylcysteine (NAC) may reduce patient-reported oxaliplatin neuropathy, but the evidence remains preliminary and heterogeneous.
Evidence at a glance
- Evidence label: Promising but insufficient randomized evidence
- Benefit: A 2026 placebo-controlled trial reported lower neuropathy scores over four FOLFOX cycles; older small studies also reported signals.
- Certainty: Low because trials are small, short and mostly single-center, use different cancers and regimens, and do not establish long-term nerve protection.
- Risk: Oral NAC commonly causes nausea and other gastrointestinal symptoms; rash or hypersensitivity is uncommon. Product quality and treatment interactions require review.
- Goal: Prevention or reduction of chemotherapy-induced peripheral neuropathy; not cancer control.
What was studied
Newest trial: Forty-six people with stage III or high-risk stage II colorectal cancer receiving modified FOLFOX-6 were randomized to oral NAC 1,200 mg one hour before oxaliplatin or placebo for four cycles (NCT07391163).
Results: The NAC arm had lower FACT/GOG-NTX-12 and clinician-graded neuropathy scores at early cycles and study end, with less pain interference but no difference in pain severity. The abstract also reported biomarker changes; biomarkers do not prove clinical nerve protection.
Earlier evidence: Small trials using 600 mg twice before oxaliplatin or other dosing strategies during paclitaxel reported favorable signals. A recent network meta-analysis also ranked NAC favorably for severe neuropathy, but its estimate inherits the limitations of the component trials.
What this evidence cannot establish
The studies do not prove prevention of persistent neuropathy after chemotherapy, preservation of dose intensity, or improved survival.
NAC formulations, doses and timing are not interchangeable, and these research regimens are not personal prescribing instructions.
Safety and practical context
Oral NAC can cause nausea, vomiting, diarrhea, abdominal discomfort and unpleasant odor or taste; rare rash or hypersensitivity has been reported.
Because antioxidants may have treatment-specific effects and the oncology evidence is not mature, the chemotherapy team should review timing, dose and product quality rather than assuming over-the-counter NAC is harmless.
Questions for the care team
- Is the goal acute symptom reduction or prevention of lasting neuropathy?
- Does the evidence match my chemotherapy drug and schedule?
- Could NAC alter other medicines or add nausea during treatment?
Sources and identifiers
- 2026 placebo-controlled colorectal-cancer trial (PMID 42909655)
- ClinicalTrials.gov NCT07391163
- Earlier oxaliplatin trial (PMID 32063109)
- Recent network meta-analysis (PMID 42876024)
- DailyMed: acetylcysteine safety information
Funding and conflicts: Funding and conflict details for the newest trial were not verified from the accessible abstract.
Source access: Original reports, abstracts/full text where available, registries and authoritative safety sources checked 11 November 2026. The newest trial was abstract-level appraisal; earlier primary abstracts and the recent evidence synthesis were used for context.
This educational evidence record is not a personal treatment recommendation. Symptom or toxicity findings do not establish tumor response, delayed recurrence or longer survival; laboratory and animal findings are not proof of clinical benefit.
